Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2007Website:
http://www.harrow.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:31:11 GMTDividend
Analysts recommendations
Institutional Ownership
HROW Latest News
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript on May 14, 2024 at 8:00 AM ET with Company Representatives Jamie Webb, Mark L. Baum, and Andrew Boll. Conference Call Participants include Jeffrey Cohen, Chase Knickerbocker, and Brooks O'Neil. Welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call.
Harrow, Inc. stocks have decreased by 45% since the spring of 2023, but the introduction of Iheezo and Vevye indicates a possible recovery. Iheezo, an eye numbing agent, has a large market potential and is projected to generate substantial profits for Harrow. Vevye, a treatment for dry eyes, also has a considerable market opportunity and has shown positive results since its launch.
- 1(current)
- 2
What type of business is Harrow Health?
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
What sector is Harrow Health in?
Harrow Health is in the Healthcare sector
What industry is Harrow Health in?
Harrow Health is in the Drug Manufacturers - Specialty & Generic industry
What country is Harrow Health from?
Harrow Health is headquartered in United States
When did Harrow Health go public?
Harrow Health initial public offering (IPO) was on 28 September 2007
What is Harrow Health website?
https://www.harrow.com
Is Harrow Health in the S&P 500?
No, Harrow Health is not included in the S&P 500 index
Is Harrow Health in the NASDAQ 100?
No, Harrow Health is not included in the NASDAQ 100 index
Is Harrow Health in the Dow Jones?
No, Harrow Health is not included in the Dow Jones index
When was Harrow Health the previous earnings report?
No data
When does Harrow Health earnings report?
The next expected earnings date for Harrow Health is 13 November 2024